Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 380 participants.

Also called NCT07249853

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 380 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07249853
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07249853. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-06 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage
Acronym
CAPTAIN
Condition
Aneurysmal Subarachnoid Hemorrhage
Intervention (Drug)
Cilostazol 100 mg BID
Intervention (Drug)
placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07249853
Content hash
042304700628d7705458abca74e2c33a7f937e3df7ceac861e760a6d29b28da0